Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Work In Process: 2017-2023

Historic Work In Process for China Pharma Holdings (CPHI) over the last 7 years, with Dec 2023 value amounting to $413,597.

  • China Pharma Holdings' Work In Process fell 50.59% to $334,430 in Q3 2024 from the same period last year, while for Sep 2024 it was $334,430, marking a year-over-year decrease of 50.59%. This contributed to the annual value of $413,597 for FY2023, which is 25.77% down from last year.
  • China Pharma Holdings' Work In Process amounted to $413,597 in FY2023, which was down 25.77% from $557,146 recorded in FY2022.
  • In the past 5 years, China Pharma Holdings' Work In Process ranged from a high of $662,999 in FY2020 and a low of $314,231 during FY2019.
  • For the 3-year period, China Pharma Holdings' Work In Process averaged around $509,296, with its median value being $557,146 (2022).
  • As far as peak fluctuations go, China Pharma Holdings' Work In Process plummeted by 36.36% in 2019, and later spiked by 110.99% in 2020.
  • Yearly analysis of 5 years shows China Pharma Holdings' Work In Process stood at $314,231 in 2019, then spiked by 110.99% to $662,999 in 2020, then declined by 15.97% to $557,146 in 2021, then remained steady at $557,146 in 2022, then declined by 25.77% to $413,597 in 2023.